S1 · E70
Thursday · 21 min
Episode 70: Cellares
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these complex, personalized medicines at commercial scale? From CAR-T to gene-edited cell therapies, the science may be advancing rapidly, but manufacturing remains labor-intensive, expensive, and difficult to scale. Cellares believes the answer is automation. We’ll break down the origins of Cellares, the engineering philosophy behind its Cell Shuttle platform, and how the company is attempting to turn cell therapy manufacturing into something closer to an automated pharmaceutical factory. We’ll also explore its partnerships with companies including Bristol Myers Squibb and Cabaletta Bio, the massive investment behind its Smart Factory network, and why pharmaceutical companies have become increasingly interested in automating cell therapy production. But there’s a major twist: Bristol Myers Squibb recently terminated its partnership with Cellares, raising questions about whether the Cell Shuttle is truly ready for commercial-scale manufacturing. We’ll unpack what happened, why manufacturing a clinical-stage therapy isn't necessarily the same as manufacturing a commercial product, and what this could mean for Cellares and the broader future of automated cell therapy. Because the next breakthrough in cell therapy may not be another drug, it may be the factory that finally makes these living medicines scalable. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Cellares #CellTherapy #CAR_T #CAR-T #Biotech #Biotechnology #Pharma #CellTherapyManufacturing #Biomanufacturing #GeneTherapy #DrugDevelopment #LifeSciences #Healthcare #BristolMyersSquibb #CabalettaBio #CellShuttle #Manufacturing #BiotechInnovation #PrecisionMedicine Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E69
August 20 · 21 min
Episode 69: Summit Therapeutics
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda. We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune checkpoint inhibition with VEGF blockade could create a powerful new approach to cancer treatment. We’ll also break down the clinical data in lung cancer, Summit’s growing pipeline, the massive commercial opportunity, and the risks surrounding regulatory approval, clinical durability, and the company’s heavy dependence on a single lead asset. But Summit’s story goes far beyond one cancer drug. Ivonescimab represents a broader shift in how medicines are discovered and commercialized, with innovative assets increasingly emerging from Chinese biotech and being licensed by Western companies for global development. Could Summit become the company that brings a new generation of cancer therapeutics to the world and could ivonescimab really become a challenger to Keytruda? 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #SummitTherapeutics #Ivonescimab #Biotech #Biotechnology #Pharma #Oncology #Cancer #CancerResearch #Immunotherapy #BispecificAntibodies #PrecisionMedicine #DrugDevelopment #ClinicalTrials #Keytruda #Merck #ChineseBiotech #Healthcare #LifeSciences #PharmaceuticalIndustry Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E68
August 13 · 23 min
Episode 68: Guardant Health
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier. We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes. Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E67
August 6 · 23 min
Episode 67: Epic Systems
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind American healthcare. From Judy Faulkner founding Epic in a Wisconsin basement to becoming the dominant electronic health record platform, Epic has transformed how hospitals, physicians, and patients interact with medical information. We'll dive into Epic's founding story, the evolution of its electronic health record, the rise of MyChart and Cosmos, and how Epic built a massive competitive moat through interoperability, data, workflow integration, and switching costs. We'll also explore its growing role in artificial intelligence, how Epic is embedding AI directly into clinical workflows, and the battle with companies like Oracle Health to control the future of healthcare data. Because the next generation of healthcare won't just be about developing better drugs and devices, it will be about who controls the information infrastructure connecting patients, providers, data, and AI. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EpicSystems #Healthcare #HealthTech #Biotech #Pharma #AI #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #JudyFaulkner #EHR #HealthData #MedTech #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
August 1 · 9 min
July 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E66
July 30 · 23 min
Episode 66: Scribe Therapeutics
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation. We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing. Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E65
July 23 · 23 min
Episode 65: Apogee Therapeutics
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation antibody engineering. Rather than chasing entirely new biological targets, Apogee is focused on improving what already works, developing longer-lasting biologics that could reduce injections from every few weeks to every few months. We'll dive into the evolution of modern immunology, the science behind cytokines and Fc engineering, how Apogee emerged from biotech incubator Paragon Therapeutics, and why investors have poured hundreds of millions of dollars into its vision. We'll also break down its pipeline, including APG777, APG808, and other promising candidates targeting eczema, asthma, inflammatory bowel disease, and beyond. Because sometimes the biggest innovation isn't discovering new biology, it's engineering better medicines for the patients who depend on them. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ApogeeTherapeutics #Biotech #Immunology #AutoimmuneDisease #Biologics #AntibodyEngineering #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Dermatology #Asthma #Inflammation #ProteinEngineering #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E64
July 16 · 23 min
Episode 64: Conception Bio
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive medicine, and regenerative science. Their mission? To make eggs from ordinary cells through in vitro gametogenesis (IVG), a breakthrough that could fundamentally change how we think about infertility, fertility preservation, and human reproduction. We'll dive into the science behind IVG, the pioneering research that made the field possible, the founders' vision, and why investors believe reproductive biology could become one of biotech's next major frontiers. We'll also discuss the enormous technical hurdles, ethical questions, and potential applications for cancer survivors, age-related infertility, LGBTQ+ family building, and beyond. Because the next revolution in medicine may not be about curing disease, it may be about creating life's very first cell. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ConceptionBio #Fertility #IVF #StemCells #RegenerativeMedicine #Biotech #ReproductiveBiology #InVitroGametogenesis #IVG #DrugDiscovery #Healthcare #LifeSciences #DevelopmentalBiology #PrecisionMedicine #WomenInScience #Biotechnology #SciencePodcast #FutureOfMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
July 9 · 23 min
Episode 63: Enveda Biosciences
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast synthetic chemical libraries, Enveda is using artificial intelligence, metabolomics, and mass spectrometry to unlock the world's largest and largely untapped chemical library: nature. We'll trace the history of natural product drug discovery, from penicillin and paclitaxel to the AI revolution, dive into founder Viswa Colluru's vision of creating a searchable map of nature's chemistry, and explore how Enveda's platform is transforming plants, fungi, and microbes into tomorrow's medicines. We'll also discuss the company's growing clinical pipeline, why investors have poured hundreds of millions into the platform, and whether AI can finally solve one of drug discovery's oldest challenges. Because sometimes, the future of medicine isn't invented, it evolves. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Enveda #ArtificialIntelligence #AI #DrugDiscovery #Biotech #NaturalProducts #MachineLearning #Metabolomics #Pharmaceuticals #Healthcare #PrecisionMedicine #MedicinalChemistry #LifeSciences #Biotechnology #Innovation #ClinicalResearch #DrugDevelopment #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E62
July 2 · 24 min
Episode 62: Isomorphic Labs
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mysteries, protein folding, to building an AI-native pharmaceutical company, Isomorphic Labs is attempting to fundamentally change how medicines are discovered. We'll dive into the origins of AlphaFold, the scientific vision of Nobel Prize-winning CEO Demis Hassabis, how AI is reshaping medicinal chemistry, and why pharmaceutical giants like Novartis and Eli Lilly are investing billions in AI-powered drug discovery partnerships. We'll also discuss the promise, challenges, and future of foundation models in biology, and whether AI can truly accelerate the journey from molecule to medicine. Because the next blockbuster drug may not be discovered by chance, it may be designed by an algorithm. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #IsomorphicLabs #DeepMind #AlphaFold #ArtificialIntelligence #AI #DrugDiscovery #Biotech #Healthcare #PrecisionMedicine #Pharmaceuticals #MachineLearning #ProteinFolding #DemisHassabis #NobelPrize #MedicinalChemistry #LifeSciences #Biology #Google #Alphabet #EliLilly #Novartis #FutureOfMedicine #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
June 30 · 10 min
June 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology power play to a flurry of high-stakes partnerships involving AI-native drug discovery and novel protein-degradation platforms, the industry spent June 2026 signaling a clear preference for integrated precision, prioritizing assets that can bypass traditional resistance mechanisms and redefine standards of care in oncology and metabolic disease. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E61
June 25 · 23 min
Episode 61: Danaher
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Business System (DBS), the acquisition strategy that reshaped biotechnology, the landmark purchases of Beckman Coulter, Pall, and Cytiva, and why Danaher became one of the biggest winners of the COVID-19 era. While biotech headlines focus on breakthrough drugs and billion-dollar acquisitions, Danaher quietly supplies the tools, diagnostics, manufacturing systems, and technologies that power modern medicine. From sequencing cancer genomes and producing monoclonal antibodies to manufacturing gene therapies and vaccines, Danaher sits behind the scenes enabling scientific innovation across the globe. We'll also discuss the leadership of Larry Culp, the company's role in the rise of biologics, gene therapies, and precision medicine, and the lessons Danaher offers about building value through infrastructure rather than blockbuster products. Because sometimes the companies changing healthcare aren't the ones discovering the drugs, they're the ones making discovery possible. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Danaher #Biotech #LifeSciences #Healthcare #Biopharma #Cytiva #PallCorporation #BeckmanCoulter #Diagnostics #GeneTherapy #CellTherapy #Biologics #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #LaboratoryScience #LarryCulp #BusinessPodcast #BiotechPodcast #HealthcareInnovation #Investing #Science #CorporateHistory #HealthcareBusiness Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E60
June 18 · 25 min
Episode 60: Hims & Hers
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story, rapid growth, SPAC-era public debut, expansion into mental health, dermatology, weight loss, and primary care, as well as the controversies surrounding compounded GLP-1 medications, regulatory scrutiny, and the broader debate around the future of telemedicine. From Silicon Valley startup to healthcare disruptor, Hims & Hers offers a fascinating case study in consumerization, accessibility, and the changing relationship between patients and providers. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #HimsAndHers #Telehealth #DigitalHealth #HealthcareInnovation #GLP1 #WeightLossDrugs #Biotech #HealthcareBusiness #StartupStories #PublicMarkets #HealthcareTechnology #DirectToConsumer #Pharma #HealthTech #BusinessPodcast #AndrewDudum #Medicine #HealthcareDisruption #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E59
June 11 · 23 min
Episode 59: Illumina
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E58
June 4 · 23 min
Episode 58: UnitedHealthcare
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States. We explore the company's founding story, the leadership of industry-defining executives, the creation of Optum, and the acquisition strategy that turned UnitedHealth into far more than an insurance company. We also unpack the controversies surrounding prior authorizations, claim denials, Medicare Advantage investigations, antitrust concerns, and the growing public frustration with the American healthcare system. Finally, we examine one of the most shocking moments in modern corporate history: the assassination of CEO Brian Thompson in 2024, the national conversation it sparked, and what it revealed about the growing tension between healthcare corporations and the patients they serve. This is a story about scale, innovation, power, controversy, and the future of healthcare itself. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #UnitedHealthcare #UnitedHealthGroup #Optum #Healthcare #HealthInsurance #MedicareAdvantage #HealthcareInnovation #HealthcareBusiness #Biotech #Pharma #HealthTech #BrianThompson #CorporateStrategy #PetriDishPerspectives #HealthcarePolicy #DigitalHealth #ValueBasedCare #ManagedCare #HealthcareEconomics #BusinessPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
June 1 · 11 min
May 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "acute care" architectures to massive investments in generative AI-driven discovery engines, the industry has clearly shifted toward a model of integrated precision, prioritizing both the speed of research and the consolidation of complex manufacturing infrastructure. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E57
May 28 · 25 min
Episode 57: 23andMe
Send us Fan Mail This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science behind SNP genotyping, the shift from ancestry testing to drug discovery partnerships with pharma giants like GSK, and the promise and limits of consumer-driven precision medicine. We also dive into the SPAC-era hype cycle, regulatory and FDA battles, privacy controversies around genetic data ownership, and the deeper ethical question at the heart of the company: who actually owns your biology once it’s been digitized? This is a story about genetics, identity, data, and the uneasy intersection of science and consumer tech. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #23andMe #Genetics #Biotech #DNA #Genomics #PrecisionMedicine #HealthcareInnovation #BioTech #Pharma #DataPrivacy #ConsumerGenomics #SPAC #DrugDiscovery #SciencePodcast #PetriDishPerspectives #Ancestry #DigitalHealth Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E56
May 21 · 23 min
Episode 56: Thermo Fisher
Send us Fan Mail This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack the company’s role during COVID-19, its expansion into CDMO services, and why some of the most powerful companies in healthcare are often the ones nobody talks about. This is the story of the invisible engine behind modern biology and the company behind the companies. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #ThermoFisher #Biotech #LifeSciences #Biotechnology #Pharma #DrugDevelopment #Genomics #Diagnostics #CDMO #HealthcareInnovation #PrecisionMedicine #Science #Biopharma #PetriDishPerspectives #LaboratoryScience #SyntheticBiology #ThermoFisherScientific Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E55
May 14 · 23 min
Episode 55: Alnylam
Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine. This is the story of persistence, platform biology, and the rise of RNA therapeutics. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E54
May 7 · 16 min
Episode 54: All about 340B
Send us Fan Mail In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But over time, it has evolved into something much bigger. We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics. Because 340B isn’t just about drug discounts. It’s about who captures value in the healthcare system and who it’s really meant to serve. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplained Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters

Showing 1–20 of 22 episodes